Scancell Hlds (SCLP) - Moditope Vaccine Technology Platform
RNS Number : 0889K
Scancell Holdings Plc
15 August 2012
15 August 2012
Scancell Holdings Plc
ModitopeÔ vaccine technology platform
Stimulation of killer CD4 T cells with potent anti-tumour activity
Scancell Holdings Plc, (AIM:SCLP), the developer of therapeutic cancer
vaccines, today announcesthedevelopment of a new platform technology
(ModitopeÔ) that stimulates the production of killer CD4 T cells with
powerful anti-tumour activity. The Directors believe that this new discovery
could have a profound effect on the way that cancer vaccines are developed.
CD4 responses to cancer associated antigens have been notoriously difficult to
generate whether presented as peptides, proteins or DNA. CD4 cells are vital
for effective anti-tumour immunity. Scancell has identified and patented a
series of modified epitopes that overcome this limitation. Scancell's
ModitopeÔ technology produces killer CD4 T cells that destroy tumours without
Professor Lindy Durrant, Joint CEO of Scancell Holdings and Professor of
Cancer Immunotherapy at Nottingham University, commented: "Not only do these
unique epitopes stimulate a CD4 killer T cell response, we have also shown in
tests that cancer patients can produce an immune response to these epitopes.
The ModitopeÔ epitopes can be used to develop both DNA and peptide vaccines
and could become an important component of many therapeutic vaccines in the
future, both under development at Scancell and other companies"
Prof Peter Stern, Head of the Cancer Research UK, Immunology Group at the
Paterson Institute for Cancer Research, commented: "This novel technology has
the potential to transform the therapeutic cancer field. It is increasingly
recognised that combining products and technologies will unlock the full
potential of cancer vaccines. The ModitopeÔ technology offers those developing
cancer vaccines, a means to optimise the potency of their immune targets".
David Evans, Chairman of Scancell Holdings, commented: "This highly innovative
discovery opens up a new approach to the development of cancer vaccines.
Whilst currently at an early stage, we are aware that the opportunities could
be considerable in addition to Scancell's existing platform technology. As a
result, the Board is actively evaluating its strategic options for this new
technology platform and will be consulting with key shareholders in this
regard. We are excited by the potential and are resolute in our aim of
creating the greatest value for shareholders. The Board will update the market
in due course."
The Directors of the issuer accept responsibility for this announcement.
For Further Information:
Dr Richard Goodfellow, Joint CEO Scancell Holdings Plc + 44 207 653 9850
Professor Lindy Durrant, Joint CEO Scancell Holdings Plc + 44 207 653 9850
Graham Herring/Heather Armstrong Newgate Threadneedle + 44 207 653 9850
Ross Andrews / Tom Rowley Zeus Capital + 44 161 831 1512
Jon Belliss/Karen Kelly Xcap Securities Plc + 44 207 101 7070
Scancell is developing novel therapeutic vaccines for the treatment of cancer
and infectious diseases based on its groundbreaking ImmunoBody® and Moditope™
technology platforms. Scancell's first cancer vaccine SCIB1 is being developed
for the treatment of melanoma and is in Phase 2 clinical trials.
Treating cancer by vaccination allows small non-toxic doses of a vaccine to be
administered to a patient, stimulating an immune response. Effective cancer
vaccines need to target dendritic cells to stimulate both parts of the
cellular immune system; the helper cell system where inflammation is
stimulated at the tumour site; and the cytotoxic T-lymphocyte or CTL response
where immune system cells are primed to recognise and kill specific cells.
A limitation of many cancer vaccines currently in development is that they
cannot specifically target dendritic cells in vivo. Several groups have
demonstrated successful vaccination by growing dendritic cells ex vivo,
pulsing them with tumour antigens and re-infusing them. However, this
procedure is patient specific, time consuming and expensive. Scancell has
developed its breakthrough patent protected ImmunoBody® technology to overcome
An ImmunoBody® is a human antibody or fusion protein engineered to express
helper cell and CTL epitopes from tumour antigens over-expressed by cancer
cells. Antibodies are ideal vectors for carrying T cell epitopes from tumour
antigens as they have long half-lives and can effectively target dendritic
cells via their Fc receptors, allowing efficient stimulation of both helper
and CTL responses.
The Immunobody® technology can be adapted to provide the basis for treating
any tumour type and may also be of potential utility in the development of
vaccines against hepatitis, HIV and other chronic infectious diseases.
Scancell has also identified and patented a series of modified epitopes that
stimulate the production of killer CD4 that destroy tumours without toxicity.
The Directors believe that the Moditope™ platform could have a profound effect
on the way that cancer vaccines are developed.
This information is provided by RNS
The company news service from the London Stock Exchange
MSCEAAPSFFEAEFF -0- Aug/15/2012 12:12 GMT
Press spacebar to pause and continue. Press esc to stop.